Estrogen Receptors

DK1 is a selective modulator of the estrogen-related receptor alpha (ERRα). It demonstrates significant biological activity by reducing blood glucose levels, making it a valuable tool for studying metabolic pathways. This compound holds potential for research applications in diabetes and related disorders.

LY117018 is a selective estrogen receptor modulator (SERM) and an analog of Raloxifene. It exhibits significant antiproliferative activity on breast cancer cell lines, making it a valuable tool for research in cancer biology and therapeutic applications targeting estrogen receptor pathways. This compound can be utilized in studies investigating the modulation of estrogen receptor activity in various cancer models.

Acolbifene hydrochloride is a selective estrogen receptor modulator (SERM) that acts as an estrogen receptor antagonist. It effectively inhibits estradiol (E2)-induced transcriptional activity of the estrogen receptors ERα and ERβ, with IC50 values of 2 nM and 0.4 nM, respectively. This compound demonstrates strong antiestrogenic activity in both the mammary gland and uterus, highlighting its potential in cancer prevention research and exploration of anticarcinogenic properties.

Cancer-Targeting Compound 1 selectively targets the estrogen receptor (ER), playing a crucial role in the modulation of estrogen-related pathways associated with hormone-driven cancers. This compound is valuable for research focused on the understanding of estrogen receptor signaling and its implications in the development and progression of breast cancer and other hormone-responsive tumors. Through its precise action on the ER, it aids in exploring potential therapeutic strategies and enhancing the knowledge of cancer biology.

(Rac)-ErSO-DFP is a selective small molecule biomodulator that targets estrogen receptor alpha (Erα). This compound enhances the Erα-dependent adaptive unfolded protein response (a-UPR), demonstrating potential therapeutic effects against ERα-positive breast cancer, including tumors that exhibit resistance to conventional treatments. Its mechanism suggests possible applications in cancer research and the development of targeted therapies for estrogen-responsive malignancies.

Raloxifene 6-Monomethyl Ether is a derivative of Raloxifene that selectively inhibits Estrogen Receptor α. This compound demonstrates significant biological activity, with an IC50 of 250 nM against MCF-7 breast cancer cells, leading to a pIC50 of 6.6. It is a valuable tool for research in hormone-dependent cancer studies and may provide insights into therapeutic strategies targeting estrogen signaling pathways.

Raloxifene 4'-glucuronide is a major metabolite of Raloxifene that functions as a selective estrogen receptor modulator. It primarily interacts with the estrogen receptor, demonstrating an IC50 of 370 μM. This compound activates the TGFβ3 promoter as a full agonist at nanomolar concentrations while inhibiting expression of the estrogen response element-containing vitellogenin promoter. Raloxifene 4'-glucuronide is useful for research applications in understanding estrogenic activity and signaling pathways.

4,4'-Oxydiphenol is a known estrogen receptor inhibitor, exhibiting an IC50 value of 60 μM. This compound manifests significant biological activity by modulating estrogen signaling pathways, making it a useful tool for exploring estrogen receptor-related mechanisms. It is pertinent for research applications in cancer biology, particularly in studies focused on hormone-dependent tumors and endocrine regulation.

2-Hydroxyestrone is a specific receptor-mediated antiestrogenic agent that plays a significant role in modulating estrogen-related pathways. This compound exhibits anticarcinogenic properties, making it valuable in cancer research and therapeutic studies. Its ability to interact with estrogen receptors positions it as a key reagent for investigating the effects of estrogen in various biological contexts.

SR-16157 is a dual-action steroid sulfatase (STS) inhibitor and selective estrogen receptor alpha (ERα) modulator, with an IC50 of 0.1 µM. This compound displays potent STS inhibitory and anti-estrogenic effects in breast cancer cells, making it a valuable tool for understanding the role of estrogen signaling in cancer progression. SR-16157 is applicable in breast cancer research, particularly in studies exploring therapeutic strategies targeting estrogen metabolism and receptor modulation.

BHPI is a selective inhibitor of the estrogen receptor ERα, regulating downstream signaling pathways by activating phospholipase C gamma (PLCγ) and inducing the unfolded protein response (UPR). This compound exhibits significant antitumor activity, making it relevant for research in breast, endometrial, and ovarian cancers. Its ability to modulate estrogen-related signaling pathways positions BHPI as a valuable tool in the study of hormone-driven malignancies and therapeutic interventions.

Estriol is an orally active estrogen that acts as an agonist of estrogen receptors ERα and ERβ. It exhibits antagonistic activity against GPR30 in estrogen receptor-negative breast cancer cells, making it a valuable compound in cancer research. Additionally, Estriol has been shown to mitigate disease severity via immunomodulatory mechanisms that reduce tissue inflammation, while also demonstrating proconvulsant properties. Its diverse biological activities make it relevant for studies on hormone-related disorders and cancer therapeutics.

Estradiol valerate is a synthetic form of the estrogen hormone with a primary mechanism as an agonist of the estrogen receptor (ER). This compound is utilized in various research applications, including hormone replacement therapy studies and investigations into estrogen-mediated biological processes. Its ability to modulate estrogen receptor activity makes it a valuable reagent for exploring the roles of estrogen in development, reproduction, and endocrine function.

Tracheloside is an antiestrogenic lignin known for promoting keratinocyte proliferation through the stimulation of the ERK1/2 signaling pathway. This compound exhibits significant potential in enhancing wound healing and tissue regeneration processes. Its ability to modulate cellular responses makes Tracheloside a valuable tool for research in dermatological and regenerative medicine applications.

Triphenylethylene is an antiestrogen agent that primarily functions by inhibiting L-type Ca2+ channels. This compound displays weak estrogenic activity and has been shown to relax duodenal intestinal muscle. Triphenylethylene is useful in research applications focusing on estrogen receptor modulation and the investigation of calcium channel dynamics in smooth muscle tissues.

Bisphenol C is a selective estrogen receptor-α (ERα) agonist and estrogen receptor-β (ERβ) antagonist, exhibiting IC50 values of 2.65 nM and 1.94 nM for ERα and ERβ, respectively. This compound is significant in research related to endocrine disruption and estrogenic activity. Its applications extend to investigating the biological effects associated with environmental exposure to endocrine disruptors found in common consumer products such as plastics and food packaging.

Dienestrol diacetate targets the estrogen receptor, functioning as a synthetic nonsteroidal phenolic compound with established estrogenic activity. It effectively mimics the effects of estrogen in vivo, influencing the reproductive system and associated biological processes. This compound is under investigation for its potential to inhibit hormone-related diseases, including those arising from estrogen deficiency, and may have applications in hormone replacement therapy.

Ethamoxytriphetol, a nonsteroidal antiestrogen, functions by blocking estrogen receptor activity, thereby inhibiting estrogen-mediated cellular processes. This compound demonstrates significant biological activity in the modulation of hormone-dependent tumors, making it valuable in cancer research, particularly in breast cancer studies. Its application extends to investigating the mechanisms of antiestrogen resistance and exploring novel therapeutic strategies.

Diethylstilbestrol diphosphate is a potent estrogen receptor agonist and a prodrug of diethylstilbestrol. It exhibits significant anti-gonadotropin activity, making it a valuable tool in the research of prostate cancer. This compound aids in elucidating mechanisms of estrogen signaling and its implications in various hormonal responses, contributing to investigations in endocrine-related cancers.